{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:39:25Z","timestamp":1793255965490,"version":"4.5.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s13555-025-01537-5","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T10:25:19Z","timestamp":1757413519000},"page":"3173-3193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons"],"prefix":"10.1007","volume":"15","author":[{"given":"Stephano","family":"Cedirian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4029-941X","authenticated-orcid":false,"given":"Luca","family":"Rapparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pampaloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"La Placa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Sgarzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Negosanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Starace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"issue":"12","key":"1537_CR1","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"JJ Meier","year":"2012","unstructured":"Meier JJ. GLP-1 receptor agonists for individualized treatment of type\u00a02 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728\u201342.","journal-title":"Nat Rev Endocrinol"},{"key":"1537_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-025-00049-3","author":"P Verdin","year":"2025","unstructured":"Verdin P. Top companies and drugs by sales in 2024. Nat Rev Drug Discov. 2025. https:\/\/doi.org\/10.1038\/d41573-025-00049-3.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"1537_CR3","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1172\/JCI78371","volume":"124","author":"LL Baggio","year":"2014","unstructured":"Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014;124(10):4223\u20136.","journal-title":"J Clin Invest"},{"issue":"7","key":"1537_CR4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463\u201374.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"1537_CR5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","volume":"31","author":"Y Xie","year":"2025","unstructured":"Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025;31(3):951\u201362.","journal-title":"Nat Med"},{"key":"1537_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108824","volume":"269","author":"A Arredouani","year":"2025","unstructured":"Arredouani A. GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders? Pharmacol Ther. 2025;269:108824.","journal-title":"Pharmacol Ther"},{"key":"1537_CR7","doi-asserted-by":"publisher","first-page":"1149328","DOI":"10.3389\/fendo.2023.1149328","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhang Q, Tan Y, et al. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. Front Endocrinol. 2023;14:1149328.","journal-title":"Front Endocrinol"},{"issue":"9","key":"1537_CR8","first-page":"34","volume":"17","author":"K Lal","year":"2024","unstructured":"Lal K, Herringshaw E. The use of GLP-1 agonists in the management of cutaneous disease. J Clin Aesthet Dermatol. 2024;17(9):34\u20137.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"4\u20135","key":"1537_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.autrev.2014.01.008","volume":"13","author":"SK Raychaudhuri","year":"2014","unstructured":"Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev. 2014;13(4\u20135):490\u20135.","journal-title":"Autoimmun Rev"},{"key":"1537_CR10","first-page":"143","volume":"14","author":"K Haran","year":"2024","unstructured":"Haran K, Johnson CE, Smith P, et al. Impact of GLP-1 receptor agonists on psoriasis and cardiovascular comorbidities: a narrative review. Psoriasis Auckl NZ. 2024;14:143\u201352.","journal-title":"Psoriasis Auckl NZ"},{"issue":"11","key":"1537_CR11","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1007\/s00125-011-2232-3","volume":"54","author":"AE Hogan","year":"2011","unstructured":"Hogan AE, Tobin AM, Ahern T, et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T\u00a0cells: lessons from obesity, diabetes and psoriasis. Diabetologia. 2011;54(11):2745\u201354.","journal-title":"Diabetologia"},{"issue":"11","key":"1537_CR12","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/j.1468-3083.2012.04609.x","volume":"27","author":"T Ahern","year":"2013","unstructured":"Ahern T, Tobin AM, Corrigan M, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type\u00a02 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013;27(11):1440\u20133.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1537_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.diabet.2011.11.004","volume":"38","author":"M Buysschaert","year":"2012","unstructured":"Buysschaert M, Tennstedt D, Preumont V. Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab. 2012;38(1):86\u20138.","journal-title":"Diabetes Metab"},{"issue":"3","key":"1537_CR14","first-page":"23","volume":"2023","author":"AE Malavazos","year":"2023","unstructured":"Malavazos AE, Meregalli C, Sorrentino F, et al. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep. 2023;2023(3):23\u20130017.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"1","key":"1537_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00592-011-0359-9","volume":"51","author":"A Faurschou","year":"2014","unstructured":"Faurschou A, Knop FK, Thyssen JP, Zachariae C, Skov L, Vilsb\u00f8ll T. Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol. 2014;51(1):147\u201350.","journal-title":"Acta Diabetol"},{"issue":"1","key":"1537_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/bjd.12380","volume":"169","author":"CT Reid","year":"2013","unstructured":"Reid CT, Tobin AM, Ahern T, O\u2019Shea D, Kirby B. Liraglutide in combination with acitretin for severe recalcitrant psoriasis. Br J Dermatol. 2013;169(1):230\u20131.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1537_CR17","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","volume":"33","author":"L Lin","year":"2022","unstructured":"Lin L, Xu X, Yu Y, et al. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type\u00a02 diabetes: a randomized-controlled trial. J Dermatolog Treat. 2022;33(3):1428\u201334.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1537_CR18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/jdv.12629","volume":"29","author":"A Faurschou","year":"2015","unstructured":"Faurschou A, Gyldenl\u00f8ve M, Rohde U, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients\u2014a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2015;29(3):555\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1537_CR19","first-page":"10007","volume":"2021","author":"G Costanzo","year":"2021","unstructured":"Costanzo G, Curatolo S, Bus\u00e0 B, Belfiore A, Gullo D. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type\u00a02 diabetic patient. Endocrinol Diabetes Metab Case Rep. 2021;2021:10007.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"2","key":"1537_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/2042018814543483","volume":"5","author":"MR Al-Badri","year":"2014","unstructured":"Al-Badri MR, Azar ST. Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis. Ther Adv Endocrinol Metab. 2014;5(2):34\u20138.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"2","key":"1537_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/exd.12081","volume":"22","author":"A Faurschou","year":"2013","unstructured":"Faurschou A, Pedersen J, Gyldenl\u00f8ve M, et al. Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol. 2013;22(2):150\u20132.","journal-title":"Exp Dermatol"},{"issue":"8","key":"1537_CR22","first-page":"1148","volume":"22","author":"SC Ku","year":"2024","unstructured":"Ku SC, Chang HC. Efficacy of glucagon-like peptide-1 receptor agonists for psoriasis: an updated systematic review and meta-analysis. J Dtsch Dermatol Ges. 2024;22(8):1148\u201352.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"11","key":"1537_CR23","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s00125-011-2297-z","volume":"54","author":"DJ Drucker","year":"2011","unstructured":"Drucker DJ, Rosen CF. Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology. Diabetologia. 2011;54(11):2741\u20134.","journal-title":"Diabetologia"},{"issue":"3","key":"1537_CR24","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/09546634.2021.1882658","volume":"33","author":"G Chang","year":"2022","unstructured":"Chang G, Chen B, Zhang L. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type\u00a02 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies. J Dermatolog Treat. 2022;33(3):1299\u2013305.","journal-title":"J Dermatolog Treat"},{"issue":"7\u20138","key":"1537_CR25","first-page":"16527","volume":"133","author":"J Nowowiejska","year":"2023","unstructured":"Nowowiejska J, Baran A, Flisiak I. The first case of psoriatic skin lesions exacerbation after liraglutide. Pol Arch Intern Med. 2023;133(7\u20138):16527.","journal-title":"Pol Arch Intern Med"},{"issue":"5","key":"1537_CR26","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","volume":"82","author":"SR Goldburg","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045\u201358.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1537_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/jdv.16677","volume":"35","author":"TV Nguyen","year":"2021","unstructured":"Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35(1):50\u201361.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"22","key":"1537_CR28","doi-asserted-by":"publisher","first-page":"8436","DOI":"10.3390\/ijms21228436","volume":"21","author":"E Del Duca","year":"2020","unstructured":"Del Duca E, Morelli P, Bennardo L, Di Raimondo C, Nistic\u00f2 SP. Cytokine pathways and investigational target therapies in hidradenitis suppurativa. Int J Mol Sci. 2020;21(22):8436.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1537_CR29","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.3390\/cells10082094","volume":"10","author":"E Scala","year":"2021","unstructured":"Scala E, Cacciapuoti S, Garzorz-Stark N, et al. Hidradenitis suppurativa: where we are and where we are going. Cells. 2021;10(8):2094.","journal-title":"Cells"},{"issue":"2","key":"1537_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40257-024-00911-x","volume":"26","author":"J Strong","year":"2025","unstructured":"Strong J, Driscoll MS. Obesity in hidradenitis suppurativa: are GLP-1 receptor agonists the new frontier? Am J Clin Dermatol. 2025;26(2):175\u201382.","journal-title":"Am J Clin Dermatol"},{"issue":"21","key":"1537_CR31","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.3390\/jcm13216292","volume":"13","author":"PK Krajewski","year":"2024","unstructured":"Krajewski PK, Z\u0142otowska A, Szepietowski JC. The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects. J Clin Med. 2024;13(21):6292.","journal-title":"J Clin Med"},{"issue":"5","key":"1537_CR32","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1111\/ijd.17108","volume":"63","author":"Y Gu","year":"2024","unstructured":"Gu Y, Sebaratnam DF. GLP-1 receptor agonists for hidradenitis suppurativa: navigating benefits, risks, and ethical considerations. Int J Dermatol. 2024;63(5):e100\u20131.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1537_CR33","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/bjd.15233","volume":"177","author":"L Jennings","year":"2017","unstructured":"Jennings L, Nestor L, Molloy O, Hughes R, Moriarty B, Kirby B. The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide. Br J Dermatol. 2017;177(3):858\u20139.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1537_CR34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.medcli.2023.11.007","volume":"162","author":"J Nicolau","year":"2024","unstructured":"Nicolau J, Nadal A, Sanch\u00eds P, Pujol A, Masmiquel L, Nadal C. Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa. Med Clin (Barc). 2024;162(3):118\u201322.","journal-title":"Med Clin (Barc)"},{"issue":"4","key":"1537_CR35","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/bjd\/ljae216","volume":"191","author":"D Lyons","year":"2024","unstructured":"Lyons D, Louly Nathan A, Pender E, et al. Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life. Br J Dermatol. 2024;191(4):631\u20133.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1537_CR36","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/ijd.16892","volume":"62","author":"T Henry","year":"2023","unstructured":"Henry T, Cahn B, Haber R, et al. Therapeutic potential of GLP-1 agonists for hidradenitis suppurativa. Int J Dermatol. 2023;62(12):1543\u20134.","journal-title":"Int J Dermatol"},{"issue":"8","key":"1537_CR37","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1111\/jocd.13544","volume":"19","author":"A Das","year":"2020","unstructured":"Das A, Datta D, Kassir M, et al. Acanthosis nigricans: a review. J Cosmet Dermatol. 2020;19(8):1857\u201365.","journal-title":"J Cosmet Dermatol"},{"issue":"6","key":"1537_CR38","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1046\/j.1365-2133.2002.05150.x","volume":"147","author":"D Torley","year":"2002","unstructured":"Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol. 2002;147(6):1096\u2013101.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1537_CR39","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2340\/00015555-1778","volume":"94","author":"B Malisiewicz","year":"2014","unstructured":"Malisiewicz B, Boehncke S, Lang V, Boehncke WH, Buerger C. Epidermal insulin resistance as a therapeutic target in acanthosis nigricans? Acta Derm Venereol. 2014;94(5):607\u20138.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1537_CR40","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1111\/pde.13206","volume":"34","author":"D Giri","year":"2017","unstructured":"Giri D, Alsaffar H, Ramakrishnan R. Acanthosis nigricans and its response to metformin. Pediatr Dermatol. 2017;34(5):e281\u20132.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"1537_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40257-019-00477-z","volume":"21","author":"I Ben Lagha","year":"2020","unstructured":"Ben Lagha I, Ashack K, Khachemoune A. Hailey-hailey disease: an update review with a focus on treatment data. Am J Clin Dermatol. 2020;21(1):49\u201368.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1537_CR42","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/ced\/llad429","volume":"49","author":"R Barry","year":"2024","unstructured":"Barry R, Murray G, Hellen R, N\u00ed Raghallaigh S. Liraglutide, a GLP-1 agonist, as a new adjunct treatment in Hailey-Hailey disease: a case report. Clin Exp Dermatol. 2024;49(4):409\u201311.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"1537_CR43","doi-asserted-by":"publisher","first-page":"367","DOI":"10.18176\/jiaci.0521","volume":"30","author":"A Carvallo","year":"2020","unstructured":"Carvallo A, Silva C, Gastaminza G, D\u2019Amelio CM. Delayed hypersensitivity reaction to liraglutide: a case report. J Investig Allergol Clin Immunol. 2020;30(5):367\u20139.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"6","key":"1537_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1210\/jcemcr\/luae105","volume":"2","author":"R Moreno-Borque","year":"2024","unstructured":"Moreno-Borque R, Guhl-Mill\u00e1n G, Mera-Carreiro S, Pazos-Guerra M, Cort\u00e9s-Toro JA, L\u00f3pez-Bran E. Delayed type hypersensitivity reaction induced by liraglutide with tolerance to semaglutide. JCEM Case Rep. 2024;2(6):105.","journal-title":"JCEM Case Rep"},{"key":"1537_CR45","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jdcr.2023.06.010","volume":"38","author":"M Yaneva","year":"2023","unstructured":"Yaneva M, Handjieva-Darlenska T, Kazandjieva J, Darlenski R. Delayed type hypersensitivity injection site reaction and tolerance induction to liraglutide for the treatment of obesity. JAAD Case Rep. 2023;38:100\u20131.","journal-title":"JAAD Case Rep"},{"issue":"5","key":"1537_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2024.101552","volume":"50","author":"C Samhani","year":"2024","unstructured":"Samhani C, Guerci B, Larose C. Cutaneous hypersensitivity reaction to dulaglutide: a case report of an allergic reaction. Diabetes Metab. 2024;50(5):101552.","journal-title":"Diabetes Metab"},{"issue":"9","key":"1537_CR47","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.2337\/dc19-0720","volume":"42","author":"O Shamriz","year":"2019","unstructured":"Shamriz O, NaserEddin A, Mosenzon O, Sviri S, Tal Y. Allergic reaction to exenatide and lixisenatide but not to liraglutide: unveiling anaphylaxis to glucagon-like peptide 1 receptor agonists. Diabetes Care. 2019;42(9):e141\u20132.","journal-title":"Diabetes Care"},{"issue":"5","key":"1537_CR48","doi-asserted-by":"publisher","first-page":"332","DOI":"10.18176\/jiaci.0274","volume":"28","author":"C Ornelas","year":"2018","unstructured":"Ornelas C, Caiado J, Lopes A, Pereira Dos Santos MC, Pereira BM. Anaphylaxis to long-acting release exenatide. J Investig Allergol Clin Immunol. 2018;28(5):332\u20134.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"5","key":"1537_CR49","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/8755122514539462","volume":"30","author":"EH Steveling","year":"2014","unstructured":"Steveling EH, Winzeler B, Bircher AJ. Systemic allergic reaction to the GLP-1 receptor agonist exenatide. J Pharm Technol. 2014;30(5):182\u20136.","journal-title":"J Pharm Technol"},{"issue":"6","key":"1537_CR50","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.jaip.2014.05.011","volume":"2","author":"E P\u00e9rez","year":"2014","unstructured":"P\u00e9rez E, Mart\u00ednez-Tadeo J, Callero A, Hern\u00e1ndez G, Rodr\u00edguez-Plata E, Garc\u00eda-Robaina JC. A case report of allergy to exenatide. J Allergy Clin Immunol Pract. 2014;2(6):822\u20133.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"1537_CR51","volume":"15","author":"Z He","year":"2023","unstructured":"He Z, Tabe AN, Rana S, King K. Tirzepatide-induced biphasic anaphylactic reaction: a case report. Cureus. 2023;15(12):e50112.","journal-title":"Cureus"},{"issue":"4","key":"1537_CR52","doi-asserted-by":"publisher","first-page":"413","DOI":"10.36849\/JDD.6550","volume":"22","author":"S Ouellette","year":"2023","unstructured":"Ouellette S, Frias G, Shah R, Alamgir M, Wassef C. Dermal hypersensitivity reaction to semaglutide: two case reports. J Drugs Dermatol JDD. 2023;22(4):413\u20136.","journal-title":"J Drugs Dermatol JDD"},{"issue":"9683","key":"1537_CR53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type\u00a02 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39\u201347.","journal-title":"Lancet"},{"issue":"1","key":"1537_CR54","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13223-023-00761-y","volume":"19","author":"OO Ye\u011fit","year":"2023","unstructured":"Ye\u011fit OO, Sar\u0131beyliler G, Karada\u011f P, et al. The first successful desensitization protocol in exenatide allergy: a case report. Allergy Asthma Clin Immunol. 2023;19(1):2.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"11","key":"1537_CR55","volume":"13","author":"N Karakousis","year":"2021","unstructured":"Karakousis N, Kostakopoulos NA, Georgakopoulou VE, Pyrgioti EE, Georgakopoulos PN. A rare case of dulaglutide-associated angioedema in a male patient. Cureus. 2021;13(11):e20041.","journal-title":"Cureus"},{"issue":"1","key":"1537_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-235663","volume":"14","author":"F Mahfooz","year":"2021","unstructured":"Mahfooz F, Aylor K, Mathew J, Reichmuth M. Extending our understanding of exenatide: a rare case of angio-oedema. BMJ Case Rep. 2021;14(1):e235663.","journal-title":"BMJ Case Rep"},{"issue":"2","key":"1537_CR57","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/ced\/llae398","volume":"50","author":"A Santana-Guti\u00e9rrez","year":"2025","unstructured":"Santana-Guti\u00e9rrez A, Bautista-G\u00f3mez AJ, Gonz\u00e1lez-Guajardo JA, Rosales-Sol\u00eds GM, Ocampo-Candiani J, Mu\u00f1oz-Garza FZ. Facial oedema and necrotic ulcers: a cutaneous reaction to liraglutide. Clin Exp Dermatol. 2025;50(2):441\u20133.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1537_CR58","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/cup.12246","volume":"41","author":"NC Boysen","year":"2014","unstructured":"Boysen NC, Stone MS. Eosinophil-rich granulomatous panniculitis caused by exenatide injection. J Cutan Pathol. 2014;41(1):63\u20135.","journal-title":"J Cutan Pathol"},{"issue":"3","key":"1537_CR59","doi-asserted-by":"publisher","first-page":"230","DOI":"10.5021\/ad.2020.32.3.230","volume":"32","author":"JW Ko","year":"2020","unstructured":"Ko JW, Park KD, Lee Y, Lee JH, Hong DK. Eosinophilic panniculitis following the subcutaneous injection of exenatide extended-release. Ann Dermatol. 2020;32(3):230\u20132.","journal-title":"Ann Dermatol"},{"issue":"6","key":"1537_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-02969-3","volume":"316","author":"CE Salazar","year":"2024","unstructured":"Salazar CE, Patil MK, Aihie O, Cruz N, Nambudiri VE. Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature. Arch Dermatol Res. 2024;316(6):248 (May\u00a025).","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"1537_CR61","volume":"14","author":"G Kyriakos","year":"2022","unstructured":"Kyriakos G, Diamantis E, Memi E, Elefsiniotis I. An uncommon case of dulaglutide-related morbilliform drug eruption. Cureus. 2022;14(1):e21536.","journal-title":"Cureus"},{"issue":"4","key":"1537_CR62","first-page":"13","volume":"13","author":"PV Rzepka","year":"2020","unstructured":"Rzepka PV, Kaffenberger JA. A case of morbilliform drug eruption to dulaglutide. J Clin Aesthetic Dermatol. 2020;13(4):13.","journal-title":"J Clin Aesthetic Dermatol"},{"issue":"2","key":"1537_CR63","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.tox.2004.12.023","volume":"209","author":"N Yawalkar","year":"2005","unstructured":"Yawalkar N. Drug-induced exanthems. Toxicology. 2005;209(2):131\u20134.","journal-title":"Toxicology"},{"issue":"3","key":"1537_CR64","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1111\/ijd.15863","volume":"61","author":"E Bostan","year":"2022","unstructured":"Bostan E, Akdogan N, Gokoz O. Paradoxical new-onset psoriasiform dermatitis associated with exenatide administration. Int J Dermatol. 2022;61(3):e112\u20134.","journal-title":"Int J Dermatol"},{"key":"1537_CR65","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jdcr.2024.10.012","volume":"56","author":"S Talasila","year":"2025","unstructured":"Talasila S, Waseh S, Liu JY, Khalifeh I, Metkowski AR, Hsu S. Semaglutide-induced fixed drug eruption. JAAD Case Rep. 2025;56:5\u20137.","journal-title":"JAAD Case Rep"},{"issue":"9","key":"1537_CR66","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1080\/03007995.2024.2386047","volume":"40","author":"MM Pinheiro","year":"2024","unstructured":"Pinheiro MM, de Souza LG, Nunes GP, et al. The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide. Curr Med Res Opin. 2024;40(9):1525\u201331.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"1537_CR67","doi-asserted-by":"publisher","first-page":"e426","DOI":"10.1093\/ajhp\/zxaf008","volume":"82","author":"J Stark","year":"2025","unstructured":"Stark J, Klass MJ, Owen L. Allodynia (skin tenderness) associated with semaglutide: a case series. Am J Health Syst Pharm. 2025;82(9):e426\u201330.","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"1537_CR68","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.jaad.2018.05.030","volume":"79","author":"O Varpuluoma","year":"2018","unstructured":"Varpuluoma O, F\u00f6rsti AK, Jokelainen J, et al. Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: a Finnish nationwide case-control study. J Am Acad Dermatol. 2018;79(6):1034-1038.e5.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1537_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13790","volume":"33","author":"K Kridin","year":"2020","unstructured":"Kridin K. Dipeptidyl-peptidase\u00a0IV inhibitors (DPP4i)-associated bullous pemphigoid: estimating the clinical profile and exploring intraclass differences. Dermatol Ther. 2020;33(4):e13790.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1537_CR70","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-021-00625-4","volume":"22","author":"PM Jedlowski","year":"2021","unstructured":"Jedlowski PM, Jedlowski MF, Fazel MT. DPP-4 inhibitors and increased reporting odds of bullous pemphigoid: a pharmacovigilance study of the FDA adverse event reporting system (FAERS) from 2006 to 2020. Am J Clin Dermatol. 2021;22(6):891\u2013900.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"1537_CR71","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamadermatol.2020.2158","volume":"156","author":"H Lee","year":"2020","unstructured":"Lee H, Chung HJ, Pawar A, Patorno E, Kim DH. Evaluation of risk of bullous pemphigoid with initiation of dipeptidyl peptidase-4 inhibitor vs second-generation sulfonylurea. JAMA Dermatol. 2020;156(10):1107\u201314.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1537_CR72","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/ggi.13799","volume":"19","author":"G Fukuda","year":"2019","unstructured":"Fukuda G, Yoshida T, Hirayama A, Umezawa Y, Takemoto M. Dulaglutide-related bullous pemphigoid in a patient with type\u00a02 diabetes: a case report. Geriatr Gerontol Int. 2019;19(12):1289\u201390.","journal-title":"Geriatr Gerontol Int"},{"issue":"5","key":"1537_CR73","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.12788\/cutis.0262","volume":"107","author":"MK Collins","year":"2021","unstructured":"Collins MK, Choudhary S, Ho J, Bunimovich YL. Bullous pemphigoid triggered by liraglutide. Cutis. 2021;107(5):E9-11.","journal-title":"Cutis"},{"key":"1537_CR74","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jdcr.2021.07.027","volume":"15","author":"CP Burruss","year":"2021","unstructured":"Burruss CP, Jones JM, Burruss JB. Semaglutide-associated bullous pemphigoid. JAAD Case Rep. 2021;15:107\u20139.","journal-title":"JAAD Case Rep"},{"issue":"3","key":"1537_CR75","first-page":"9676","volume":"15","author":"B Sonego","year":"2023","unstructured":"Sonego B, Zelin E, Zalaudek I, di Meo N. Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature. Dermatol Rep. 2023;15(3):9676.","journal-title":"Dermatol Rep"},{"issue":"5","key":"1537_CR76","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jdiacomp.2012.05.018","volume":"26","author":"F Besemer","year":"2012","unstructured":"Besemer F, Verschoor AJ, Diamant M, Hoogma RPLM. Vesiculopustular dermatosis: an uncommon side-effect of liraglutide? J Diabetes Complications. 2012;26(5):458\u20139.","journal-title":"J Diabetes Complications"},{"issue":"10","key":"1537_CR77","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/ijd.14272","volume":"58","author":"CR Hamann","year":"2019","unstructured":"Hamann CR, Chung C, Kaffenberger BH. Pyoderma gangrenosum associated with dulaglutide therapy. Int J Dermatol. 2019;58(10):1202\u20134.","journal-title":"Int J Dermatol"},{"issue":"2","key":"1537_CR78","doi-asserted-by":"publisher","DOI":"10.1097\/JW9.0000000000000143","volume":"10","author":"OO Ogunremi","year":"2024","unstructured":"Ogunremi OO, Ismail SF, Dhami RK, Newton JS, Kindle SA, Kozmenko V. A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists. Int J Womens Dermatol. 2024;10(2):e143.","journal-title":"Int J Womens Dermatol"},{"issue":"25","key":"1537_CR79","first-page":"00198","volume":"S0190\u20139622","author":"SW Cho","year":"2025","unstructured":"Cho SW, Sontam T, Chen A, Limmer EE, Tolkachjov SN. Glucagon-like peptide-1 receptor agonist use is associated with increased rates of acne vulgaris diagnosis in nondiabetic obese women but not men: a retrospective cohort study. J Am Acad Dermatol. 2025;S0190\u20139622(25):00198\u2013207.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1537_CR80","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1001\/jamadermatol.2019.1893","volume":"155","author":"AL Cogen","year":"2019","unstructured":"Cogen AL, Desai K, Elder D, Rosenbach M. Acute photodistributed exanthematous pustulosis associated with liraglutide treatment. JAMA Dermatol. 2019;155(10):1198\u2013200.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1537_CR81","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1111\/jdv.20197","volume":"39","author":"H Godfrey","year":"2025","unstructured":"Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R. Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol. 2025;39(2):e153\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1537_CR82","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jaad.2025.01.046","volume":"92","author":"O Burke","year":"2025","unstructured":"Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study. J Am Acad Dermatol. 2025;92(5):1141\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"2\u20133","key":"1537_CR83","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.regpep.2006.02.007","volume":"134","author":"JF List","year":"2006","unstructured":"List JF, He H, Habener JF. Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin. Regul Pept. 2006;134(2\u20133):149\u201357.","journal-title":"Regul Pept"},{"issue":"9","key":"1537_CR84","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/ijd.17246","volume":"63","author":"DD Desai","year":"2024","unstructured":"Desai DD, Sikora M, Nohria A, et al. GLP-1 agonists and hair loss: a call for further investigation. Int J Dermatol. 2024;63(9):1128\u201330.","journal-title":"Int J Dermatol"},{"issue":"2","key":"1537_CR85","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/jdv.20512","volume":"39","author":"MG Buontempo","year":"2025","unstructured":"Buontempo MG, Santos BT. Exploring the hair loss risk in glucagon-like peptide-1 agonists: emerging concerns and clinical implications. J Eur Acad Dermatol Venereol. 2025;39(2):263\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1537_CR86","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1055\/a-2148-6321","volume":"39","author":"CD Humphrey","year":"2023","unstructured":"Humphrey CD, Lawrence AC. Implications of ozempic and other semaglutide medications for facial plastic surgeons. Facial Plast Surg. 2023;39(6):719\u201321.","journal-title":"Facial Plast Surg"},{"issue":"6","key":"1537_CR87","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1055\/s-0044-1785450","volume":"39","author":"MB Hansen","year":"2023","unstructured":"Hansen MB, Krogh Pedersen KL, Jia T. Letter to the Editor: comment on implications of ozempic and other semaglutide medications for facial plastic surgeons. Facial Plast Surg. 2023;39(6):e2-3.","journal-title":"Facial Plast Surg"},{"key":"1537_CR88","unstructured":"Ozempic. Patient Information Leaflet. Novo Nordisk. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/209637s025lbl.pdf. Accessed Aug 1, 2025."},{"key":"1537_CR89","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.bjps.2024.07.051","volume":"96","author":"MR Mansour","year":"2024","unstructured":"Mansour MR, Hannawa OM, Yaldo MM, Nageeb EM, Chaiyasate K. The rise of \u2018ozempic face\u2019: analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. J Plast Reconstr Aesthet Surg. 2024;96:225\u20137.","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"2","key":"1537_CR90","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.16716","volume":"24","author":"D Haykal","year":"2025","unstructured":"Haykal D, Hersant B, Cartier H, Meningaud JP. The role of GLP-1 agonists in esthetic medicine: exploring the impact of semaglutide on body contouring and skin health. J Cosmet Dermatol. 2025;24(2):e16716.","journal-title":"J Cosmet Dermatol"},{"issue":"12","key":"1537_CR91","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1111\/jocd.16013","volume":"22","author":"L Schelke","year":"2023","unstructured":"Schelke L, Harris S, Cartier H, et al. Treating facial overfilled syndrome with impaired facial expression\u2013presenting clinical experience with ultrasound imaging. J Cosmet Dermatol. 2023;22(12):3252\u201360.","journal-title":"J Cosmet Dermatol"},{"issue":"7","key":"1537_CR92","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1097\/SCS.0000000000010588","volume":"35","author":"CN de Oliveira","year":"2024","unstructured":"de Oliveira CN, Bisson GB, Piedade E, Osny FJ. Late facial edema after lip filling with hyaluronic acid: possible association with the use of ozempic. J Craniofac Surg. 2024;35(7):2110\u20132.","journal-title":"J Craniofac Surg"},{"issue":"1","key":"1537_CR93","volume":"12","author":"ES O\u2019Neill","year":"2024","unstructured":"O\u2019Neill ES, Wiegmann AL, Parrella N, Pittman T, Hood K, Kurlander D. Injectable weight loss medications in plastic surgery: what we know, perioperative considerations, and recommendations for the future. Plast Reconstr Surg. 2024;12(1):e5516.","journal-title":"Plast Reconstr Surg"},{"issue":"10","key":"1537_CR94","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/asj\/sjae085","volume":"44","author":"JA Toms","year":"2024","unstructured":"Toms JA, O\u2019Neill E, Wiegmann AL, Adepoju J, Raj MS. Prevalence patterns of body contouring procedures among injectable glucagon-like peptide-1 receptor agonist users. Aesthet Surg J. 2024;44(10):1072\u20139.","journal-title":"Aesthet Surg J"},{"key":"1537_CR95","doi-asserted-by":"publisher","unstructured":"Taraschi F, Salgarello M. GLP-1 agonists in plastic surgery: impact on aesthetic outcomes-two case reports. Aesthetic Plast Surg. 2025. https:\/\/doi.org\/10.1007\/s00266-025-04703-4.","DOI":"10.1007\/s00266-025-04703-4"},{"issue":"1","key":"1537_CR96","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/SAP.0000000000004089","volume":"94","author":"EW Stanton","year":"2025","unstructured":"Stanton EW, Manasyan A, Banerjee R, Hong K, Koesters E, Daar DA. Glucagon-like peptide-1 agonists: a practical overview for plastic and reconstructive surgeons. Ann Plast Surg. 2025;94(1):121\u20137.","journal-title":"Ann Plast Surg"},{"key":"1537_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107192","volume":"90","author":"JB He","year":"2021","unstructured":"He JB, Ma XY, Li WJ, Liu YY, Lin DS. Exenatide inhibits necrosis by enhancing angiogenesis and ameliorating ischemia\/reperfusion injury in a random skin flap rat model. Int Immunopharmacol. 2021;90:107192.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1537_CR98","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12933-023-01897-2","volume":"22","author":"NCC Werkman","year":"2023","unstructured":"Werkman NCC, Driessen JHM, Stehouwer CDA, et al. The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study. Cardiovasc Diabetol. 2023;22(1):160.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"1537_CR99","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/jbcr\/irae189","volume":"46","author":"A Manasyan","year":"2025","unstructured":"Manasyan A, Cannata B, Ross E, et al. The emerging role of GLP-1 agonists in burn care: what do we know? J Burn Care Res. 2025;46(2):481\u20136.","journal-title":"J Burn Care Res"},{"issue":"1","key":"1537_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0041-1727202","volume":"38","author":"CW Patterson","year":"2022","unstructured":"Patterson CW, Palines PA, Bartow MJ, et al. Stratification of surgical risk in DIEP breast reconstruction based on classification of obesity. J Reconstr Microsurg. 2022;38(1):1\u20139.","journal-title":"J Reconstr Microsurg"},{"issue":"3","key":"1537_CR101","doi-asserted-by":"publisher","first-page":"629e","DOI":"10.1097\/PRS.0000000000011418","volume":"154","author":"ZM Borab","year":"2024","unstructured":"Borab ZM, Fisher SM, Gimenez A, Raskin P, Valek T, Rohrich RJ. Emerging role of semaglutide and GLP-1 agonist medications in plastic surgery: a note of caution. Plast Reconstr Surg. 2024;154(3):629e-e631.","journal-title":"Plast Reconstr Surg"},{"issue":"3","key":"1537_CR102","first-page":"244","volume":"5","author":"W Ghnnam","year":"2016","unstructured":"Ghnnam W, Elrahawy A, Moghazy ME. The effect of body mass index on outcome of abdominoplasty operations. World J Plast Surg. 2016;5(3):244\u201351.","journal-title":"World J Plast Surg"},{"issue":"4","key":"1537_CR103","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/PRS.0000000000009986","volume":"151","author":"JI Payton","year":"2023","unstructured":"Payton JI, Abraham JT, Novak MD, Monsivais SE, Hammonds KP, Altman AM. Impact of age, body mass index, and resection weight on postoperative complications in reduction mammaplasty. Plast Reconstr Surg. 2023;151(4):727\u201335.","journal-title":"Plast Reconstr Surg"},{"key":"1537_CR104","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.2147\/DDDT.S312347","volume":"15","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Chen R, Jia Y, Chen M, Shuai Z. Effects of exenatide on coagulation and platelet aggregation in patients with type\u00a02 diabetes. Drug Des Devel Ther. 2021;15:3027\u201340.","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"1537_CR105","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/PRS.0000000000007021","volume":"146","author":"AK Greene","year":"2020","unstructured":"Greene AK, Zurakowski D, Goss JA. Body mass index and lymphedema morbidity: comparison of obese versus normal-weight patients. Plast Reconstr Surg. 2020;146(2):402\u20137.","journal-title":"Plast Reconstr Surg"},{"issue":"6","key":"1537_CR106","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.mayocp.2020.10.002","volume":"96","author":"KJ Pfeifer","year":"2021","unstructured":"Pfeifer KJ, Selzer A, Mendez CE, et al. Preoperative management of endocrine, hormonal, and urologic medications: society for perioperative assessment and quality improvement (SPAQI) consensus statement. Mayo Clin Proc. 2021;96(6):1655\u201369.","journal-title":"Mayo Clin Proc"},{"key":"1537_CR107","unstructured":"Centre for Perioperative Care. Guideline for perioperative care for people with diabetes mellitus undergoing elective and emergency surgery. CPOC, 2021. https:\/\/cpoc.org.uk\/sites\/cpoc\/files\/documents\/2021-03\/CPOC-Diabetes-Guideline2021_0.pdf. Accessed Aug 15, 2023."},{"key":"1537_CR108","unstructured":"American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. https:\/\/www.asahq.org\/about-asa\/newsroom\/news-releases\/2023\/06\/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative. Accessed May\u00a01, 2025."},{"issue":"387","key":"1537_CR109","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080340","volume":"22","author":"W Alkabbani","year":"2024","unstructured":"Alkabbani W, Suissa K, Gu KD, et al. Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study. BMJ. 2024;22(387):e080340.","journal-title":"BMJ"},{"issue":"2","key":"1537_CR110","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1053\/j.gastro.2024.03.015","volume":"167","author":"YH Yeo","year":"2024","unstructured":"Yeo YH, Gaddam S, Ng WH, et al. Increased risk of aspiration pneumonia associated with endoscopic procedures among patients with glucagon-like peptide 1 receptor agonist use. Gastroenterology. 2024;167(2):402\u20134043.","journal-title":"Gastroenterology"},{"issue":"3","key":"1537_CR111","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/EJA.0000000000001914","volume":"41","author":"K Gariani","year":"2024","unstructured":"Gariani K, Putzu A. Glucagon-like peptide-1 receptor agonists in the perioperative period: implications for the anaesthesiologist. Eur J Anaesthesiol. 2024;41(3):245\u20136.","journal-title":"Eur J Anaesthesiol"},{"key":"1537_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.10.003","author":"TL Kindel","year":"2024","unstructured":"Kindel TL, Wang AY, Wadhwa A, et al. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Clin Gastroenterol Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.cgh.2024.10.003.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"384","key":"1537_CR113","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410","volume":"29","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type\u00a02 diabetes: systematic review and network meta-analysis. BMJ. 2024;29(384):e076410.","journal-title":"BMJ"},{"issue":"11","key":"1537_CR114","volume":"16","author":"FA Alghamdi","year":"2024","unstructured":"Alghamdi FA, Alshegifi HA, Alhuthayli RS, et al. Bridging the gap between diabetes and cardiovascular disease: a comparative review of different glucagon-like peptide-1 (GLP-1) agonists: efficacy, safety, and patient outcomes. Cureus. 2024;16(11):e74345.","journal-title":"Cureus"},{"issue":"3\u20134","key":"1537_CR115","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","volume":"11","author":"TD Filippatos","year":"2014","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11(3\u20134):202\u201330.","journal-title":"Rev Diabet Stud"},{"issue":"276","key":"1537_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2024.114474","volume":"15","author":"S Fulton","year":"2024","unstructured":"Fulton S, Horn CC, Zhang C. Characterizing a new tool to manipulate area postrema GLP1R+ neurons across species. Physiol Behav. 2024;15(276):114474.","journal-title":"Physiol Behav"},{"issue":"1","key":"1537_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgae719","volume":"110","author":"RJ Jalleh","year":"2024","unstructured":"Jalleh RJ, Plummer MP, Marathe CS, et al. Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide. J Clin Endocrinol Metab. 2024;110(1):1\u201315.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1537_CR118","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/gastroent15010014","volume":"15","author":"J Wan","year":"2024","unstructured":"Wan J, Ferrari C, Tadros M. GLP-1RA essentials in gastroenterology: side effect management, precautions for endoscopy and applications for gastrointestinal disease treatment. Gastroenterol Insights. 2024;15(1):191\u2013212.","journal-title":"Gastroenterol Insights"},{"issue":"5","key":"1537_CR119","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/dmrr.499","volume":"20","author":"MS Fineman","year":"2004","unstructured":"Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type\u00a02 diabetes. Diabetes Metab Res Rev. 2004;20(5):411\u20137.","journal-title":"Diabetes Metab Res Rev"},{"key":"1537_CR120","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/jcpt.13225","volume":"45","author":"J Trujillo","year":"2020","unstructured":"Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type\u00a02 diabetes. J Clin Pharm Ther. 2020;45:43\u201360.","journal-title":"J Clin Pharm Ther"},{"issue":"18","key":"1537_CR121","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","volume":"330","author":"M Sodhi","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023;330(18):1795\u20137.","journal-title":"JAMA"},{"issue":"5","key":"1537_CR122","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.2337\/db11-1109","volume":"61","author":"B Gier","year":"2012","unstructured":"Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes. 2012;61(5):1250\u201362.","journal-title":"Diabetes"},{"issue":"5","key":"1537_CR123","first-page":"G984","volume":"275","author":"A Wettergren","year":"1998","unstructured":"Wettergren A, W\u00f8jdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol. 1998;275(5):G984-992.","journal-title":"Am J Physiol"},{"issue":"1","key":"1537_CR124","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","volume":"141","author":"M Elashoff","year":"2011","unstructured":"Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150\u20136.","journal-title":"Gastroenterology"},{"key":"1537_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol. 2022;13:1043789.","journal-title":"Front Endocrinol"},{"issue":"6","key":"1537_CR126","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/14740338.2023.2284992","volume":"23","author":"A Muhammed","year":"2024","unstructured":"Muhammed A, Thomas C, Kalaiselvan V, Undela K. Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials. Expert Opin Drug Saf. 2024;23(6):731\u201342.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"1537_CR127","doi-asserted-by":"publisher","first-page":"206","DOI":"10.23736\/S2724-6507.20.03219-8","volume":"48","author":"B Nreu","year":"2023","unstructured":"Nreu B, Dicembrini I, Tinti F, Mannucci E, Monami M. Pancreatitis and pancreatic cancer in patients with type\u00a02 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials. Minerva Endocrinol. 2023;48(2):206\u201313.","journal-title":"Minerva Endocrinol"},{"issue":"1","key":"1537_CR128","first-page":"64","volume":"62","author":"S Jeyaraj","year":"2014","unstructured":"Jeyaraj S, Shetty AS, Kumar CRR, et al. Liraglutide-induced acute pancreatitis. J Assoc Physicians India. 2014;62(1):64\u20136.","journal-title":"J Assoc Physicians India"},{"issue":"5","key":"1537_CR129","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513\u20139.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"1537_CR130","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMp1314078","volume":"370","author":"AG Egan","year":"2014","unstructured":"Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs\u2013FDA and EMA assessment. N Engl J Med. 2014;370(9):794\u20137.","journal-title":"N Engl J Med"},{"issue":"1","key":"1537_CR131","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50408","volume":"7","author":"R Dankner","year":"2024","unstructured":"Dankner R, Murad H, Agay N, Olmer L, Freedman LS. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type\u00a02 diabetes. JAMA Netw Open. 2024;7(1):e2350408.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"1537_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102834","volume":"17","author":"L Nagendra","year":"2023","unstructured":"Nagendra L, Bg H, Sharma M, Dutta D. Semaglutide and cancer: a systematic review and meta-analysis. Diabetes Metab Syndr. 2023;17(9):102834.","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"1537_CR133","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc22-1148","volume":"46","author":"J Bezin","year":"2023","unstructured":"Bezin J, Gouverneur A, P\u00e9nichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46(2):384\u201390.","journal-title":"Diabetes Care"},{"issue":"3","key":"1537_CR134","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/dom.15382","volume":"26","author":"GA Silverii","year":"2024","unstructured":"Silverii GA, Monami M, Gallo M, et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024;26(3):891\u2013900.","journal-title":"Diabetes Obes Metab"},{"key":"1537_CR135","unstructured":"Questions and Answers - Safety Requirements for Victoza (liraglutide). FDA. 2018 Mar 11. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/questions-and-answers-safety-requirements-victoza-liraglutide. Accessed 2025 May\u00a01."},{"key":"1537_CR136","unstructured":"MOUNJARO. Patient Information Leaflet. Eli Lilly. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215866s031lbl.pdf. Accessed Aug 1, 2025."},{"issue":"19","key":"1537_CR137","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/CIRCULATIONAHA.124.070766","volume":"150","author":"G Sharma","year":"2024","unstructured":"Sharma G. Treating reproductive-aged women with glucagon-like peptide-1 receptor agonists: what are the clinical considerations? Circulation. 2024;150(19):1487\u20139.","journal-title":"Circulation"},{"issue":"5","key":"1537_CR138","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40264-023-01392-3","volume":"47","author":"B Calvarysky","year":"2024","unstructured":"Calvarysky B, Dotan I, Shepshelovich D, Leader A, Cohen TD. Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review. Drug Saf. 2024;47(5):439\u201351.","journal-title":"Drug Saf"},{"key":"1537_CR139","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-024-01339-y","author":"J Duah","year":"2025","unstructured":"Duah J, Seifer D. Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review. Reprod Biol Endocrinol. 2025. https:\/\/doi.org\/10.1186\/s12958-024-01339-y.","journal-title":"Reprod Biol Endocrinol"},{"issue":"4","key":"1537_CR140","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1111\/bcp.16354","volume":"91","author":"J Zhou","year":"2025","unstructured":"Zhou J, Wei Z, Lai W, Liu M, Wu X. The safety profile of usage of glucagon-like peptide-1 receptor agonists in pregnancy: a pharmacovigilance analysis based on the food and drug administration adverse event reporting system. Br J Clin Pharmacol. 2025;91(4):1272\u201380.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1537_CR141","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/dom.15459","volume":"26","author":"D Lau","year":"2024","unstructured":"Lau D, Gamble JM. Suicidality among users of glucagon-like peptide-1 receptor agonists: an emerging signal? Diabetes Obes Metab. 2024;26(4):1150\u20136.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"1537_CR142","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.23385","volume":"7","author":"G Schoretsanitis","year":"2024","unstructured":"Schoretsanitis G, Weiler S, Barbui C, Raschi E, Gastaldon C. Disproportionality analysis from World Health Organization data on semaglutide, liraglutide, and suicidality. JAMA Netw Open. 2024;7(8):e2423385.","journal-title":"JAMA Netw Open"},{"issue":"388","key":"1537_CR143","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080679","volume":"26","author":"SB Shapiro","year":"2025","unstructured":"Shapiro SB, Yin H, Yu OHY, Rej S, Suissa S, Azoulay L. Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type\u00a02 diabetes: active comparator, new user cohort study. BMJ. 2025;26(388):e080679.","journal-title":"BMJ"},{"issue":"11","key":"1537_CR144","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1001\/jamainternmed.2024.4369","volume":"184","author":"P Ueda","year":"2024","unstructured":"Ueda P, S\u00f6derling J, Wintzell V, et al. GLP-1 receptor agonist use and risk of suicide death. JAMA Intern Med. 2024;184(11):1301\u201312.","journal-title":"JAMA Intern Med"},{"issue":"11","key":"1537_CR145","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1007\/s00125-024-06243-z","volume":"67","author":"I Hurtado","year":"2024","unstructured":"Hurtado I, Robles C, Peir\u00f3 S, Garc\u00eda-Sempere A, Sanf\u00e9lix-Gimeno G. Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study. Diabetologia. 2024;67(11):2471\u201380.","journal-title":"Diabetologia"},{"issue":"8","key":"1537_CR146","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.7326\/M24-0329","volume":"177","author":"H Tang","year":"2024","unstructured":"Tang H, Lu Y, Donahoo WT, et al. Glucagon-like peptide-1 receptor agonists and risk for suicidal ideation and behaviors in U.S. older adults with type\u00a02 diabetes: a target trial emulation study. Ann Intern Med. 2024;177(8):1004\u201315.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1537_CR147","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","volume":"30","author":"W Wang","year":"2024","unstructured":"Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30(1):168\u201376.","journal-title":"Nat Med"},{"key":"1537_CR148","unstructured":"Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13\u201316 January 2025. EMA. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-january-2025. Accessed Aug 1, 2025."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01537-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01537-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01537-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T18:02:54Z","timestamp":1761242574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01537-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":148,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1537"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01537-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stephano Cedirian, Monia Donati, Luca Rapparini, Francesca Pampaloni, Michelangelo La Placa, Rossella Sgarzani, Luca Negosanti, Emanuel Raschi and Michela Starace is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Michela Starace was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}